The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor

被引：0
|
作者：
Nenad Sarapa
Margaret R. Britto
Michelle B. Mainka
Kourosh Parivar
机构：
[1] Clinical PK/PD,Pfizer Global Research & Development
[2] Clinical Pharmacology,Quintiles Inc.
[3] Statistics and Programming,Pfizer Global Research & Development
来源：
European Journal of Clinical Pharmacology | 2005年 / 61卷
关键词：
Valdecoxib; Pharmacokinetics; Hepatic impairment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：247 / 256
页数：9
相关论文
共 50 条
  • [1] The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor
    Sarapa, N
    Britto, MR
    Mainka, MB
    Parivar, K
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (04) : 247 - 256
  • [2] No influence of moderate hepatic impairment on the pharmacokinetics of lumiracoxib, an oral COX-2 selective inhibitor
    Kalbag, J
    Yeh, CM
    Milosavljev, S
    Lasseter, K
    Oberstein, S
    Rordorf, C
    PHARMACOLOGICAL RESEARCH, 2004, 50 (02) : 181 - 186
  • [3] Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice
    Zhang, JY
    Yuan, JJ
    Wang, YF
    Bible, RH
    Breau, AP
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (04) : 491 - 501
  • [4] Valdecoxib: A highly selective and potent inhibitor of COX-2
    Gierse, JK
    Koboldt, C
    Hood, B
    Zhang, Y
    Zweifel, B
    Kurumbail, R
    Kiefer, J
    Pawlitz, J
    Walker, M
    Isakson, P
    Seibert, K
    FASEB JOURNAL, 2002, 16 (04): : A181 - A182
  • [5] Valdecoxib (Bextra) -: A new COX-2 inhibitor
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2002, 44 (1129): : 39 - 40
  • [6] Valdecoxib: the rise and fall of a COX-2 inhibitor
    Atukorala, Inoshi
    Hunter, David J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (08) : 1077 - 1086
  • [7] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod
    Zhang, Peijin
    Hosein, Fareeda
    Yu, Kyungha
    Walker, Susan
    Syto, Mary
    Tirucherai, Giridhar
    Murthy, Bindu
    Tatosian, Daniel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S843 - S843
  • [8] EFFECT OF MILD AND MODERATE HEPATIC IMPAIRMENT ON QUIZARTINIB PHARMACOKINETICS
    Zahir, H.
    Lasseter, K.
    Marbury, T.
    Rondon, J.
    Bermudez, Y.
    Gammon, G.
    Kamel, Y. Mostafa
    Said, N.
    Hsu, C.
    Abutarif, M.
    Zheng, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S20 - S20
  • [9] Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
    Kletzl, Heidemarie
    Ajmi, Hassan
    Antys, Izabela
    Heinig, Katja
    Jaber, Birgit
    Marbury, Thomas C.
    Young, Annie
    Gunther, Andreas
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (08) : 3749 - 3759
  • [10] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod
    Zhang, Peijin
    Hosein, Fareeda
    Yu, Kyungha
    Walker, Susan
    Syto, Mary
    Tirucherai, Giridhar
    Murthy, Bindu
    Tatosian, Daniel
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 976 - 976
12345